CrystecPharma signed a letter of understanding with Iconovo to develop innovative dry powder inhaler solutions for the treatment of patients with lung diseases, including pulmonary fibrosis. Direct delivery of medications into the lungs permits their rapid uptake via a non-invasive route. The two key factors that determine successful…
Collaboration Between CrystecPharma and Iconovo Aims to Develop Better Inhaler Solutions for Patients
Learning that you or a loved one might need a lung transplant is scary. You probably have a lot of questions, and may wonder whether they are the right ones. You want to know if you are looking in the right place for answers. Talking with your doctors…
We all know about the benefits of exercise and try our best to incorporate it into our lives. While engaging in physical activity is difficult when living with a chronic lung condition, doctors and physical therapists recommend that those with idiopathic pulmonary fibrosis (IPF) stay as active as possible.
The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and treating idiopathic pulmonary fibrosis (IPF). The study, called PRECISIONS (for Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection), is being funded by a $22 million grant from the National Institutes of Health and …
Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with idiopathic pulmonary fibrosis (IPF), real-world data from the PROOF registry show. The results were reported in “Longitudinal clinical outcomes in a real-world population of patients with idiopathic…
I am passionate about professional development and ongoing learning opportunities. While I have always thought about these in the context of my education or career, I am looking forward to the learning that will emerge from the PFF Summit 2019 in San Antonio. I will be attending thanks to…
Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is a modification of AdAlta’s original lead candidate for the treatment of pulmonary fibrosis…
Ah, November. Tis the season for declining mental health! The end of fall and beginning of winter always make me anxious. In the past, it was the start of my competitive ski racing season that caused a lot of stress. After that were college midterms. There is no particular…
Activating a dopamine receptor on fibroblast cells (connective tissue cells) may help slow, or even reverse, fibrosis in mice, a study suggests. The study, “Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis,” was published in the journal Science Translational Medicine. Fibrosis — abnormal…
Before I got sick, my life was pretty straightforward. I knew what I wanted to study in college, and I earned my bachelor’s and master’s degrees. And although I have struggles in the workplace due to living with idiopathic pulmonary fibrosis (IPF), I am lucky to have a career…
